Eris Lifesciences Limited (ERIS) - Net Assets

Latest as of March 2026: Rs38.96 Billion INR ≈ $421.30 Million USD

Based on the latest financial reports, Eris Lifesciences Limited (ERIS) has net assets worth Rs38.96 Billion INR (≈ $421.30 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs73.66 Billion ≈ $796.55 Million USD) and total liabilities (Rs34.70 Billion ≈ $375.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ERIS strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs38.96 Billion
% of Total Assets	52.89%
Annual Growth Rate	35.95%
5-Year Change	104.15%
10-Year Change	621.52%
Growth Volatility	28.3

Eris Lifesciences Limited - Net Assets Trend (2012–2026)

This chart illustrates how Eris Lifesciences Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ERIS stock market capitalisation.

Annual Net Assets for Eris Lifesciences Limited (2012–2026)

The table below shows the annual net assets of Eris Lifesciences Limited from 2012 to 2026. Also explore net asset growth rate of Eris Lifesciences Limited to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2026-03-31	Rs38.96 Billion ≈ $421.30 Million	+19.07%
2025-03-31	Rs32.72 Billion ≈ $353.83 Million	+1.54%
2024-03-31	Rs32.22 Billion ≈ $348.45 Million	+45.09%
2023-03-31	Rs22.21 Billion ≈ $240.16 Million	+16.38%
2022-03-31	Rs19.08 Billion ≈ $206.36 Million	+21.05%
2021-03-31	Rs15.76 Billion ≈ $170.48 Million	+21.61%
2020-03-31	Rs12.96 Billion ≈ $140.19 Million	+10.91%
2019-03-31	Rs11.69 Billion ≈ $126.40 Million	+31.93%
2018-03-31	Rs8.86 Billion ≈ $95.81 Million	+64.09%
2017-03-31	Rs5.40 Billion ≈ $58.39 Million	+66.62%
2016-03-31	Rs3.24 Billion ≈ $35.04 Million	+20.20%
2015-03-31	Rs2.70 Billion ≈ $29.16 Million	+49.06%
2014-03-31	Rs1.81 Billion ≈ $19.56 Million	+63.18%
2013-03-31	Rs1.11 Billion ≈ $11.99 Million	+109.52%
2012-03-31	Rs528.98 Million ≈ $5.72 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Eris Lifesciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs138.50 Million	0.35%
Other Comprehensive Income	Rs38.89 Billion	99.65%
Total Equity	Rs39.03 Billion	100.00%

Eris Lifesciences Limited Competitors by Market Cap

The table below lists competitors of Eris Lifesciences Limited ranked by their market capitalization.

Company	Market Cap
IBF Financial Holdings Co Ltd TW:2889	$1.98 Billion
AVI LTD (UNSP.ADR)/5 F:IZ60	$1.98 Billion
Hefei Metalforming Mach Tool SHG:603011	$1.98 Billion
Neutron Holdings, Inc. Common Stock NASDAQ:LIME	$1.98 Billion
Atea ASA OL:ATEA	$1.98 Billion
Pfizer Limited NSE:PFIZER	$1.98 Billion
L1 Group Limited AU:L1G	$1.98 Billion
Anywhere Real Estate Inc NYSE:HOUS	$1.98 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Eris Lifesciences Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 28,543,600,000 to 39,026,700,000, a change of 10,483,100,000 (36.7%).
Net income of 6,195,200,000 contributed positively to equity growth.
New share issuances of 44,800,000 increased equity.
Other comprehensive income increased equity by 38,701,800,000.
Other factors decreased equity by 34,458,700,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs6.20 Billion	+15.87%
Share Issuances	Rs44.80 Million	+0.11%
Other Comprehensive Income	Rs38.70 Billion	+99.17%
Other Changes	Rs-34.46 Billion	-88.3%
Total Change	Rs-	36.73%

Book Value vs Market Value Analysis

This analysis compares Eris Lifesciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.63x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 379.37x to 4.63x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-03-31	Rs3.48	Rs1321.30	x
2013-03-31	Rs7.72	Rs1321.30	x
2014-03-31	Rs12.84	Rs1321.30	x
2015-03-31	Rs19.32	Rs1321.30	x
2016-03-31	Rs23.33	Rs1321.30	x
2017-03-31	Rs39.27	Rs1321.30	x
2018-03-31	Rs62.64	Rs1321.30	x
2019-03-31	Rs83.59	Rs1321.30	x
2020-03-31	Rs94.41	Rs1321.30	x
2021-03-31	Rs116.01	Rs1321.30	x
2022-03-31	Rs140.41	Rs1321.30	x
2023-03-31	Rs161.27	Rs1321.30	x
2024-03-31	Rs189.92	Rs1321.30	x
2025-03-31	Rs209.39	Rs1321.30	x
2026-03-31	Rs285.56	Rs1321.30	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Eris Lifesciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 15.87%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 19.80%
• Asset Turnover: 0.42x
• Equity Multiplier: 1.89x
Recent ROE (15.87%) is below the historical average (31.98%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	77.14%	13.49%	2.68x	2.13x	Rs321.54 Million
2013	54.86%	14.81%	2.29x	1.62x	Rs475.89 Million
2014	39.90%	13.84%	1.88x	1.53x	Rs527.69 Million
2015	33.59%	16.36%	1.53x	1.34x	Rs626.67 Million
2016	41.63%	22.37%	1.43x	1.30x	Rs1.01 Billion
2017	45.71%	32.93%	1.17x	1.19x	Rs1.93 Billion
2018	34.15%	35.56%	0.57x	1.70x	Rs2.08 Billion
2019	25.28%	30.07%	0.62x	1.35x	Rs1.76 Billion
2020	22.87%	28.02%	0.68x	1.20x	Rs1.67 Billion
2021	22.53%	29.78%	0.65x	1.16x	Rs1.97 Billion
2022	21.28%	30.62%	0.58x	1.19x	Rs2.15 Billion
2023	17.40%	23.00%	0.45x	1.67x	Rs1.63 Billion
2024	15.16%	19.69%	0.28x	2.73x	Rs1.33 Billion
2025	12.33%	12.22%	0.41x	2.46x	Rs664.04 Million
2026	15.87%	19.80%	0.42x	1.89x	Rs2.29 Billion

Industry Comparison

This section compares Eris Lifesciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $55,732,551,119
Average return on equity (ROE) among peers: 12.78%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Eris Lifesciences Limited (ERIS)	Rs38.96 Billion	77.14%	0.89x	$1.98 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$354.09 Million	3.07%	2.25x	$31.32 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.00 Billion	13.75%	2.66x	$426.21 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.31 Million	-8.08%	0.08x	$804.25 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$6.27 Billion
Ajanta Pharma Limited (AJANTPHARM)	$29.96 Billion	21.83%	0.26x	$4.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$33.31 Billion	7.66%	0.64x	$1.30 Billion
Alkem Laboratories Limited (ALKEM)	$75.58 Billion	20.97%	0.52x	$7.07 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.29 Billion	15.52%	0.29x	$154.33 Million
Alembic Pharmaceuticals Limited (APLLTD)	$52.38 Billion	9.95%	0.36x	$1.80 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$326.47 Billion	10.68%	0.52x	$10.79 Billion

About Eris Lifesciences Limited

NSE:ERIS India Drug Manufacturers - Specialty & Generic

Market Cap

$1.98 Billion

Rs183.11 Billion INR

Market Cap Rank

#6254 Global

#282 in India

Share Price

Rs1321.30

Change (1 day)

+0.81%

52-Week Range

Rs1271.00 - Rs1701.30

All Time High

Rs1847.70